The Personalized Depression Treatment Success Story You'll Never Be Able To > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapies and medication isn't effective. A customized treatment may be the solution.

Cue is an intervention platform for digital devices that converts passively collected sensor data from smartphones into customized micro-interventions designed to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to identify their feature predictors and uncover distinct features that are able to change mood as time passes.

Predictors of Mood

Depression is a major cause of mental illness in the world.1 Yet the majority of people with the condition receive treatment. To improve outcomes, healthcare professionals must be able to identify and treat patients who are the most likely to respond to specific treatments.

The treatment of depression can be personalized to help. Utilizing sensors for mobile phones, an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from the treatments they receive. With two grants totaling over $10 million, they will employ these tools to identify the biological and behavioral factors that determine response to antidepressant medications and psychotherapy.

The majority of research to the present has been focused on sociodemographic and clinical characteristics. These include demographic factors like age, sex and educational level, clinical characteristics like symptoms severity and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these variables can be predicted from information in medical records, very few studies have employed longitudinal data to study the causes of mood among individuals. Few also take into account the fact that mood can vary significantly between individuals. Therefore, it is crucial to develop methods that allow for the identification of individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can identify various patterns of behavior and emotions that vary between individuals.

In addition to these modalities the team also developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm combines the individual differences to produce an individual "digital genotype" for each participant.

The digital phenotype was associated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. The correlation was weak, however (Pearson r = 0,08, P-value adjusted by BH 3.55 x 10 03) and varied significantly among individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1, but it is often untreated and not diagnosed. In addition an absence of effective interventions and stigma associated with depressive disorders prevent many people from seeking help.

To allow for individualized shock Treatment For depression to improve treatment, identifying the patterns that can predict symptoms is essential. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only detect a few features associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous digital behavioral phenotypes collected from smartphone sensors with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements. They also capture a variety of distinct behaviors and patterns that are difficult to document using interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment depending on the degree of their depression. Patients with a CAT DI score of 35 or 65 were given online support via a coach and those with a score 75 patients were referred for psychotherapy in-person.

Participants were asked a set of questions at the beginning of the study regarding their demographics and psychosocial traits. The questions included education, age, sex and gender, financial status, marital status as well as whether they divorced or not, current suicidal ideas, intent or attempts, as well as the frequency with which they consumed alcohol. Participants also scored their level of depression severity on a 0-100 scale using the CAT-DI. The CAT-DI test was carried out every two weeks for those who received online support, and weekly for those who received in-person care.

Predictors of the Reaction to Treatment

Research why is cbt used in the treatment of depression focusing on personalized treatment for depression. Many studies are focused on identifying predictors, which will help clinicians identify the most effective medications to treat each patient. Pharmacogenetics, in particular, identifies genetic variations that determine how the body's metabolism reacts to drugs. This lets doctors select the medication that are most likely to work for every patient, minimizing the amount of time epilepsy and depression treatment effort required for trials and errors, while eliminating any adverse effects.

Another promising approach is building prediction models using multiple data sources, such as clinical information and neural imaging data. These models can be used to identify which variables are most predictive of a particular outcome, such as whether a medication can help with symptoms or mood. These models can be used to determine a patient's response to an existing treatment, allowing doctors to maximize the effectiveness of their current treatment.

A new generation of machines employs machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects of multiple variables and increase the accuracy of predictions. These models have shown to be useful for forecasting treatment outcomes, such as the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the norm in the future treatment.

In addition to prediction models based on ML, research into the underlying mechanisms of depression is continuing. Recent research suggests that depression is linked to the malfunctions of certain neural networks. This suggests that the treatment for depression will be individualized based on targeted treatments that target these circuits in order to restore normal functioning.

One method of doing this is by using internet-based programs which can offer an personalized and customized experience for patients. One study discovered that a web-based treatment was more effective than standard treatment in reducing symptoms and ensuring the best quality of life for those with MDD. A controlled, randomized study of a customized treatment for depression showed that a significant percentage of participants experienced sustained improvement and fewer side consequences.

Predictors of Side Effects

A major issue in personalizing depression treatment involves identifying and predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients have a trial-and error approach, using a variety of medications prescribed until they find one that is effective and tolerable. Pharmacogenetics offers a fresh and exciting way to select antidepressant drugs that are more effective and precise.

Many predictors can be used to determine which antidepressant to prescribe, including gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and co-morbidities. To identify the most reliable and valid predictors of a specific treatment, controlled trials that are randomized with larger numbers of participants will be required. This is because the detection of interaction effects or moderators can be a lot more difficult in trials that only take into account a single episode of treatment for anxiety and depression near me per patient instead of multiple episodes of treatment over a period of time.

Furthermore the prediction of a patient's response to a particular medication will also likely require information on the symptom profile and comorbidities, in addition to the patient's prior subjective experience with tolerability and efficacy. At present, only a few easily identifiable sociodemographic and clinical variables are believed to be correlated with response to MDD like age, gender race/ethnicity BMI, the presence of alexithymia, and the severity of depression symptoms.

Many challenges remain in the application of pharmacogenetics to treat depression treatment without medication. First, a clear understanding of the genetic mechanisms is required and an understanding of what constitutes a reliable predictor for treatment response. Additionally, ethical issues like privacy and the responsible use of personal genetic information must be considered carefully. Pharmacogenetics can eventually help reduce stigma around mental health treatments and improve treatment outcomes. As with any psychiatric approach, it is important to give careful consideration and implement the plan. At present, it's recommended to provide patients with a variety of medications for depression that work and encourage them to talk openly with their doctors.